# Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)

Study · id `cardio:ct-nct04474223` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04474223](<https://clinicaltrials.gov/study/NCT04474223>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04474223

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1300 participants.

## Technical summary

Registry record NCT04474223. Allocation not applicable; no masking; primary purpose treatment. Start 2020-08-01 (actual); primary completion 2028-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1300 participants (planned count; ClinicalTrials.gov record NCT04474223, source copy `cardio:ctgov-nct04474223-2026-08-25`, retrieved 2026-10-26)
- Started: 2020-08-01 (actual) (ClinicalTrials.gov record NCT04474223, source copy `cardio:ctgov-nct04474223-2026-08-25`, retrieved 2026-10-26)
- Primary completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT04474223, source copy `cardio:ctgov-nct04474223-2026-08-25`, retrieved 2026-10-26)
- Completion: 2029-06-30 (anticipated) (ClinicalTrials.gov record NCT04474223, source copy `cardio:ctgov-nct04474223-2026-08-25`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT04474223, source copy `cardio:ctgov-nct04474223-2026-08-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04474223-2026-08-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
- Condition: AVB - Atrioventricular Block
- Condition: Fetal AVB
- Intervention (Drug): Dexamethasone
- Intervention (Drug): IVIG
- Lead sponsor: NYU Langone Health
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Heart block (`cardio:heart-block`)
- Registry lists this organization as the lead sponsor: NYU Langone Health (`cardio:org-nyu-langone-health`)

## Provenance

Content hash: 28ab77f6c8856253ca55f65af637ef0a390e328817764e5dcdcf3b8f5e98e2f4
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
